Dermata Therapeutics (DRMA) vs Purple Biotech (PPBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dermata Therapeutics is the larger company by market cap ($2.5 million vs $1.9 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRMA | PPBT |
|---|---|---|
| Share price | $0.5095 | $1.53 |
| Market cap | $2.51M | $1.86M |
| 1-day change | -4.23% | -4.09% |
| EPS (TTM) | $-3.28 | $-47.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-7.56M | $-26.39M |
| 52-week high | $4.66 | $8.90 |
| 52-week low | $0.50 | $0.91 |
| Distance from 52-week high | -89.07% | -82.87% |
| Analyst consensus | none | none |
| Avg. price target upside | +685.08% | +1014.75% |
| Average volume | 2.78M | 1.26M |
| Shares outstanding | 4.93M | 1.22M |
| Employees | 9 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dermata Therapeutics
DRMA stock →Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Purple Biotech
PPBT stock →Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
DRMA vs PPBT FAQ
Which is bigger, Dermata Therapeutics or Purple Biotech?
Dermata Therapeutics (DRMA) is larger, with a market capitalization of $2.51M compared with $1.86M for Purple Biotech (PPBT).
Are Dermata Therapeutics and Purple Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.